TY - JOUR
T1 - Dual Role of Chitin as the Double Edged Sword in Controlling the NLRP3 Inflammasome Driven Gastrointestinal and Gynaecological Tumours
AU - Dhanjal, Chetan Roger
AU - Lingamsetty, Rathnamegha
AU - Pareddy, Anooshka
AU - Kim, Se Kwon
AU - Raval, Ritu
N1 - Funding Information:
This work was financed by TECHSHILA-The Student Major Project of MIT through Manipal Academy of Funding: Higher Education (MAHE)-2021-22. (MIT/StudentProject-Biomachines/2021).
Funding Information:
This work was supported by TECHSHILA-The Student Major Project of MIT.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/7/11
Y1 - 2022/7/11
N2 - The role of NLRP3 in the tumour microenvironment is elusive. In some cancers, the activation of NLRP3 causes a worse prognosis and in some cancers, NLRP3 increases chances of survivability. However, in many cases where NLRP3 has a protumorigenic role, inhibition of NLRP3 would be a crucial step in therapy. Consequently, activation of NLRP3 would be of essence when inflammation is required. Although many ways of inhibiting and activating NLRP3 in cancers have been discussed before, not a lot of focus has been given to chitin and chitosan in this context. The availability of these marine compounds and their versatility in dealing with inflammation needs to be investigated further in relation with cancers, along with other natural extracts. In this review, the effects of NLRP3 on gastrointestinal and gynaecological cancers and the impact of different natural extracts on NLRP3s with special emphasis on chitin and chitosan is discussed. A research gap in using chitin derivatives as anti/pro-inflammatory agents in cancer treatment has been highlighted.
AB - The role of NLRP3 in the tumour microenvironment is elusive. In some cancers, the activation of NLRP3 causes a worse prognosis and in some cancers, NLRP3 increases chances of survivability. However, in many cases where NLRP3 has a protumorigenic role, inhibition of NLRP3 would be a crucial step in therapy. Consequently, activation of NLRP3 would be of essence when inflammation is required. Although many ways of inhibiting and activating NLRP3 in cancers have been discussed before, not a lot of focus has been given to chitin and chitosan in this context. The availability of these marine compounds and their versatility in dealing with inflammation needs to be investigated further in relation with cancers, along with other natural extracts. In this review, the effects of NLRP3 on gastrointestinal and gynaecological cancers and the impact of different natural extracts on NLRP3s with special emphasis on chitin and chitosan is discussed. A research gap in using chitin derivatives as anti/pro-inflammatory agents in cancer treatment has been highlighted.
UR - http://www.scopus.com/inward/record.url?scp=85135282227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135282227&partnerID=8YFLogxK
U2 - 10.3390/md20070452
DO - 10.3390/md20070452
M3 - Review article
C2 - 35877745
AN - SCOPUS:85135282227
SN - 1660-3397
VL - 20
JO - Marine Drugs
JF - Marine Drugs
IS - 7
M1 - 452
ER -
